Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 125

1.

The association of cytopenias and weight loss with hepatitis C virus virologic response in HIV/HCV-coinfected patients treated with PEG-IFN and RBV.

Slim J, Mildvan D, Han J, Korner E.

J Int Assoc Provid AIDS Care. 2013 Sep-Oct;12(5):354-62. doi: 10.1177/2325957413494828. Epub 2013 Jul 19.

PMID:
23873217
2.

Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV genotype 1 and HIV-1: a phase 3 study.

Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A, Lenz O, Ouwerkerk-Mahadevan S, Peeters M, De La Rosa G, Tambuyzer L, Jessner W.

Clin Infect Dis. 2014 Dec 1;59(11):1579-87. doi: 10.1093/cid/ciu675. Epub 2014 Sep 5.

PMID:
25192745
3.

Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.

Cotte L, Braun J, Lascoux-Combe C, Vincent C, Valantin MA, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker JP, Molina JM; French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group..

Clin Infect Dis. 2014 Dec 15;59(12):1768-76. doi: 10.1093/cid/ciu659. Epub 2014 Aug 18.

PMID:
25139963
4.

Ribavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort Study.

Kovari H, Russmann S, Ledergerber B, Müller D, Rotger M, Velli P, Cavassini M, Ambrosioni J, Bregenzer A, Stöckle M, Bernasconi E, Rauch A, Speck RF; Swiss HIV Cohort Study..

PLoS One. 2015 Jul 28;10(7):e0133879. doi: 10.1371/journal.pone.0133879. eCollection 2015.

5.

Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study.

Pontali E, Angeli E, Cattelan AM, Maida I, Nasta P, Verucchi G, Caputo A, Iannacone C, Puoti M.

Antivir Ther. 2015;20(1):39-48. doi: 10.3851/IMP2781. Epub 2014 May 15.

PMID:
24831457
6.

Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women.

Nasta P, Maida I, Cattelan AM, Pontali E, Angeli E, Giralda M, Verucchi G, Caputo A, Iannacone C, Puoti M, Carosi G.

J Womens Health (Larchmt). 2015 Feb;24(2):159-64. doi: 10.1089/jwh.2014.4796. Epub 2015 Feb 3.

PMID:
25682817
7.

Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers in HIV/Hepatitis C Virus-Coinfected Patients.

Bedimo R, Kang M, Tebas P, Overton ET, Hollabaugh K, McComsey G, Bhattacharya D, Evans C, Brown TT, Taiwo B.

AIDS Res Hum Retroviruses. 2016 Apr;32(4):325-8. doi: 10.1089/AID.2015.0204. Epub 2015 Nov 24.

8.

A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin.

Reiberger T, Payer BA, Ferlitsch A, Sieghart W, Breitenecker F, Aichelburg MC, Schmied B, Rieger A, Trauner M, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab and Vienna HIV & Liver Study Group..

Antivir Ther. 2012;17(7):1327-34. doi: 10.3851/IMP2349. Epub 2012 Sep 5.

PMID:
22948263
9.

Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.

Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Loncá M, Martinez E, Sánchez-Tapias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J.

J Acquir Immune Defic Syndr. 2007 Feb 1;44(2):174-8.

PMID:
17106276
10.

Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.

Ramos B, Núñez M, Rendón A, Berdún MA, Losada E, Santos I, Echevarría S, Ocampo A, Miralles C, Arazo P, Barreiro P, Romero M, Labarga P, Guardiola JM, Garcia-Samaniego J, Soriano V.

J Viral Hepat. 2007 Jun;14(6):387-91.

PMID:
17501758
11.

Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.

Sede M, Laufer N, Ojeda D, Gun A, Cahn P, Quarleri J.

Arch Virol. 2013 Sep;158(9):1907-15. doi: 10.1007/s00705-013-1687-6. Epub 2013 Apr 4.

PMID:
23553458
12.

Impact of peginterferon alpha and ribavirin treatment on lipid profiles and insulin resistance in Hepatitis C virus/HIV-coinfected persons: the AIDS Clinical Trials Group A5178 Study.

Butt AA, Umbleja T, Andersen JW, Sherman KE, Chung RT; ACTG A5178 Study Team..

Clin Infect Dis. 2012 Sep;55(5):631-8. Epub 2012 May 4.

13.

Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.

Jabłonowska E, Piekarska A, Koślińska-Berkan E, Omulecka A, Szymańska B, Wójcik K.

Acta Biochim Pol. 2012;59(3):333-7. Epub 2012 Aug 27.

14.

Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV.

Rivero-Juarez A, Mira JA, Camacho A, Neukam K, Perez-Camacho I, Caruz A, Macias J, Torre-Cisneros J, Pineda JA, Rivero A.

Infection. 2013 Feb;41(1):21-6. doi: 10.1007/s15010-012-0352-4. Epub 2012 Oct 14.

PMID:
23065463
15.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

16.

HCV clearance from saliva of HIV-HCV-coinfected patients on treatment with interferon plus ribavirin.

Feijoo J, Eirea M, Limeres J, Abeleira M, Ramos I, Ocampo A, Diz P.

Oral Dis. 2014 Apr;20(3):313-8. doi: 10.1111/odi.12116. Epub 2013 Apr 22.

PMID:
23607445
17.

Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients.

Núñez M, Mariño A, Miralles C, Berdún MA, Sola J, Hernandez-Burruezo JJ, Galindo MJ, Barreiro P, Martin-Carbonero L, Soriano V.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):439-44. Erratum in: J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):528. Mariño, Angel [corrected to Mariño, Ana].

PMID:
17468669
18.

Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C.

Piedoux S, Monnet E, Piroth L, Montange D, Royer B, Thevenot T, Kantelip JP, Di Martino V, Muret P; RibAct group..

Antivir Ther. 2011;16(8):1317-26. doi: 10.3851/IMP1920.

PMID:
22155913
19.

Open, randomized, multicentre italian trial on PEG-IFN plus ribavirin versus PEG-IFN monotherapy for chronic hepatitis C in HIV-coinfected patients on HAART.

Cargnel A, Angeli E, Mainini A, Gubertini G, Giorgi R, Schiavini M, Duca P; Italian Co-infection Study (ICOS) Group..

Antivir Ther. 2005;10(2):309-17.

PMID:
15865225
20.

Simeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparison.

Andersohn F, Claes AK, Kulp W, Mahlich J, Rockstroh JK.

BMC Infect Dis. 2016 Jan 11;16:10. doi: 10.1186/s12879-015-1311-3. Review.

Supplemental Content

Support Center